ReviewDrug, healthcare and patient safety2018
Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.
Review in Drug, healthcare and patient safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Role of Cannabis in the Management of Chronic Non-Cancer Pain: A Narrative Review.Clinics and practice · 2025Review
- School Nurse Perspectives of Medical Cannabis Policy in K-12 Schools: An Exploratory Descriptive Study.The Journal of school nursing : the official publication of the National Association of School Nurses · 2024Article
- Effects of cannabidiol on AMPKα2 /HIF-1α/BNIP3/NIX signaling pathway in skeletal muscle injury.Frontiers in pharmacology · 2024Article
- The use and potential abuse of psychoactive plants in southern Africa: an overview of evidence and future potential.Frontiers in pharmacology · 2024Review
- CBD Inhibits In Vivo Development of Human Breast Cancer Tumors.International journal of molecular sciences · 2023Article
- Treating Epilepsy with Natural Products: Nonsense or Possibility?Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- The ethics and management of cannabis use in pregnancy following decriminalisation and licensing for medical use: narrative review.BJPsych bulletin · 2023Review
- Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target.International journal of molecular sciences · 2022Review
- Analyzing the Impact of Cannabinoids on the Treatment of Spinal Disorders.Current reviews in musculoskeletal medicine · 2022Review
- Cannabis with breast cancer treatment: propitious or pernicious?3 Biotech · 2022Article
- Medical Use of Cannabis in Africa: The Pharmacists' Perspective.Innovations in pharmacy · 2022Article
- The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson's Disease: A Systematic Literature Review of Pre-Clinical Studies.Brain sciences · 2021Review
- Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence.Medical cannabis and cannabinoids · 2021Review
- Review
- Cannabis Use in People With Obsessive-Compulsive Symptomatology: Results From a Mexican Epidemiological Sample.Frontiers in psychiatry · 2021Article
- Marijuana: A systems-based primer of adverse effects associated with use and an overview of its therapeutic utility.SAGE open medicine · 2021Review
- Article
- Considerations and Implications of Cannabidiol Use During Pregnancy.Current pain and headache reports · 2020Review
- CBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1β.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the proposed Canadian July 2018 legalization of marijuana through the Cannabis Act, a thorough critical analysis of the current trials on the efficacy of medicinal marijuana (MM) as a treatment option is necessary. This review is particularly important for primary care physicians whose patients may be interested in using MM as an alternative therapy. In response to increased interest in MM, Health Canada released a document in 2013 for general practitioners (GPs) as an educational tool on the efficacy of MM in treating some chronic and acute conditions. Although additional studies have filled in some of the gaps since the release of the Health Canada document, conflicting and inconclusive results continue to pose a challenge for physicians. This review aims to supplement the Health Canada document by providing physicians with a critical yet concise update on the recent advancements made regarding the efficacy of MM as a potential therapeutic option. An update to the literature of 2013 is important given the upcoming changes in legislation on the use of marijuana. Also, we briefly highlight the current recommendations provided by Canadian medical colleges on the parameters that need to be considered prior to authorizing MM use, routes of administration as well as a general overview of the endocannabinoid system as it pertains to cannabis. Lastly, we outline the appropriate medical conditions for which the authorization of MM may present as a practical alternative option in improving patient outcomes as well as individual considerations of which GPs should be mindful. The purpose of this paper is to offer physicians an educational tool that provides a necessary, evidence-based analysis of the therapeutic potential of MM and to ensure physicians are making decisions on the therapeutic use of MM in good faith.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.